| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:15253041 | IVTH | 0.000001 - 0.001 M | 0.00004 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:15261991 | IVTH | 0.000005 - 0.00005 M | 0.000005 - 0.00005 M | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000005 - 0.00005 M | 0.000005 - 0.00005 M | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| PMID:16324804 | IVR | 200 mg/kg/day | 200 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Affects innate immunity | Immunological endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000003 - 0.000025 M | 0.000025 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000003 - 0.000025 M | 0.0000008 - 0.0000016 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:21722721 | IVR | 0.02 mg/kg | 0.02 mg/kg | Affects anogenital distance | Reproductive endocrine-mediated perturbations |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Increased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Decreased thymus gland weights | Immunological endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg | 0.002 mg/kg | Increased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 0.002 mg/kg | 0.002 mg/kg | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Decreased thymus gland weights | Immunological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Increased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Affects anogenital distance | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.